Skip to content

Whittier Daily News

66°F
Tuesday, November 25th 2025

e-Edition

Trending:

Recent Quotes
My Watchlist
Indicators
Local Stocks
San Gabriel Valley
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S Common Stock (NY:NVO)

46.81 +1.84 (+4.09%)
Streaming Delayed Price Updated: 12:17 PM EST, Nov 25, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Novo Nordisk A/S Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Novo Nordisk’s Experimental GLP-1 Drug Shows Weight Loss, Blood Sugar Levels Reduction In Study ↗
Via Stocktwits
News headline image
Novo Nordisk (NYSE:NVO) Presents a Compelling Case for Value Investors ↗
Discover Novo Nordisk (NVO), a potentially undervalued stock with strong profitability, solid financial health, and a good dividend yield. 
Via Chartmill
Novo Nordisk Stock Tumbles: HSBC Downgrades After ‘Lottery Ticket’ Alzheimer’s Bet Fails, But Retail Traders Call Selloff ‘Ridiculous’ ↗
Via Stocktwits
News headline image
Why Novo Nordisk Stock Sank 5.6% Today ↗
Semaglutide was no better than a placebo. 
Via The Motley Fool
Topics Stocks
News headline image
Hims, Block, and NRG Just Launched Huge Stock Buybacks ↗
Via MarketBeat
News headline image
Biggest Stock Movers Today, Nov. 24: AVGO, NVO, & More ↗
Stocks were up sharply to start the holiday week. 
Via The Motley Fool
Topics Artificial Intelligence Government Stocks
Novo’s Obesity Drug Patients Granted Compensation In Denmark Over Rare Eye Disease Linked To Wegovy, Ozempic ↗
Via Stocktwits
News headline image
Wondering what's happening in today's pre-market session? ↗
Let's have a look at what is happening on the US markets before the opening bell on Monday. Below you can find the top gainers and losers in today's pre-market session. 
Via Chartmill
News headline image
Novo Nordisk’s Blockbuster Drug Fails To Slow Alzheimer’s Disease Progression In Studies ↗
The company said that it is discontinuing the trials. 
Via Stocktwits
News headline image
Novo Nordisk Just Took a Big Swing, Slashing Its GLP-1 Drug Prices. Will It Pay Off for the Healthcare Giant? ↗
The obesity drug producer has taken some hits throughout the past year, but it is beginning to punch back. 
Via The Motley Fool
Topics Government
News headline image
2 Major Stocks Want to Dominate the GLP-1 Market. Which One Looks Like the Leader Heading Into 2026? ↗
Many other drugmakers are attempting to break this duopoly, but this may not happen anytime soon. 
Via The Motley Fool
News headline image
3 Top Dividend Stocks to Buy in November ↗
November is a great month to be thankful for opportunities to invest in these fantastic companies. 
Via The Motley Fool
Topics Bonds Economy
News headline image
Big News for Novo Nordisk Stock Investors ↗
Millions of people in the world are overweight, and Novo Nordisk hopes to capture a growing share of this lucrative treatment opportunity. 
Via The Motley Fool
News headline image
What's Going On With Novo Nordisk Stock? ↗
The management team conducted a cost-cutting effort that is likely to result in a more efficient business. 
Via The Motley Fool
News headline image
Vanda Reports Big Win In Wegovy Support Study, Analysts Upbeat ↗
Vanda's tradipitant cut Wegovy-related vomiting by 50% in a new trial, prompting bullish analyst views and price targets. 
Via Benzinga
News headline image
KeyCorp Delivers Sobering Outlook for LifeMD, Slashing Price Target Amidst Operational Headwinds
KeyCorp, through its KeyBanc capital markets division, has issued a significantly more pessimistic forecast for LifeMD (NASDAQ: LFMD) stock, dramatically lowering its price objective to $8.00 from a... 
Via MarketMinute
News headline image
Novo Nordisk Just Made a Big Move in the Weight Loss Drug Market. Should You Worry About Rival Eli Lilly? ↗
Novo Nordisk just addressed a problem that has prevented some from taking these drugs. 
Via The Motley Fool
News headline image
HIMS Has Been a Roller Coaster Ride. Should Investors Hop On? ↗
Via MarketBeat
News headline image
Down 45% Year-to-Date, Novo Nordisk Ignites a Price War ↗
Via MarketBeat
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
European ADRs Navigate Choppy Waters: Pharma Sector Shows Resilience Amidst Broader Market Volatility
European American Depositary Receipts (ADRs) have recently experienced a period of significant fluctuation, reflecting a broader climate of market volatility that has ripple across global financial... 
Via MarketMinute
Topics Artificial Intelligence Economy Supply Chain
News headline image
Should Investors Buy Novo Nordisk Stock Near Its Near 52-Week Low? ↗
Novo Nordisk is investing aggressively to improve its pipeline of drugs in development. 
Via The Motley Fool
News headline image
Eli Lilly on "Stock Split Watch": A Deep Dive into a Pharmaceutical Giant's Future
Indianapolis, IN – November 19, 2025 – Eli Lilly and Company (NYSE: LLY), the pharmaceutical titan, finds itself at the epicenter of market speculation, firmly placed on "stock split watch" as its... 
Via MarketMinute
News headline image
Why Big Pharma Won't Quit the Diet. Who Will Win the Next Weight Loss Battle? ↗
The next generation of weight loss drugs will hit the market in 2026. Eli Lilly and Novo Nordisk are racing to the finish line. 
Via The Motley Fool
News headline image
Can AI Drive Peloton's Comeback? ↗
The market is hopping with interesting news. 
Via The Motley Fool
Topics Artificial Intelligence
News headline image
Side Effects From Wegovy? This Vanda Pharmaceuticals' Drug Halves Vomiting In Patients ↗
Vanda Pharmaceuticals' tradipitant successfully reduced Wegovy-induced vomiting by 50% in a clinical trial. Phase 3 anticipated in H1 2026. 
Via Benzinga
News headline image
Oprah Winfrey-Backed Wellness Stock Stumbles As GLP-1 Boom Reshapes Consumer Habits: Growth Score Plummets ↗
Prominent weight-loss and wellness company, WW International Inc. (NASDAQ: WW), backed by renowned talk show host Oprah Winfrey, has seen better days, with the company filing for bankruptcy early this... 
Via Benzinga
Topics Bankruptcy
News headline image
Price Over Earnings Overview: Novo Nordisk ↗
 
Via Benzinga
News headline image
Hedge Funds Snap Up Eli Lilly, United Healthcare, And More, Putting Healthcare ETFs Back In The Spotlight ↗
With funds buying Eli Lilly, UNH, and other pharma giants, healthcare ETFs can emerge as key beneficiaries of a broader defensive rotation. 
Via Benzinga
Topics ETFs
News headline image
Novo Nordisk Leans Into Affordability Amid Rising Competition ↗
Novo Nordisk offers limited-time $199 pricing on Wegovy and Ozempic, lowers self-pay costs, and prepares for a stronger Wegovy pill rollout. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
95 96 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.